International Ophthalmology

, Volume 31, Issue 6, pp 525–527

Lamellar macular hole following intravitreal pegaptanib sodium (Macugen) injection for diabetic macular edema

Authors

    • Department of Ophthalmology, Ospedali RiunitiUniversity of Foggia
    • Department of Ophthalmology, Centre Hospitalier Intercommunal de CreteilUniversity Paris Est Creteil
    • Policlinico Riuniti di FoggiaUniversity of Foggia
  • Anna V. Bux
    • Department of Ophthalmology, Ospedali RiunitiUniversity of Foggia
  • Cristiana Iaculli
    • Department of Ophthalmology, Ospedali RiunitiUniversity of Foggia
  • Nicola Delle Noci
    • Department of Ophthalmology, Ospedali RiunitiUniversity of Foggia
Case Report

DOI: 10.1007/s10792-011-9493-1

Cite this article as:
Querques, G., Bux, A.V., Iaculli, C. et al. Int Ophthalmol (2011) 31: 525. doi:10.1007/s10792-011-9493-1

Abstract

To report on a patient who developed a lamellar macular hole 1 month after an intravitreal pegaptanib sodium injection. Interventional case report. A 66 year old patient developed a lamellar macular hole 1 month after an intravitreal pegaptanib sodium injection for diabetic macular edema (DME). The pathogenesis of the lamellar macular hole in our case can be attributed to the intravitreal injection that may have induced vitreous incarceration, causing vitreoretinal traction at the macula and development of a lamellar macular hole. Alternatively or in association, pegaptanib itself may have caused the lamellar macular hole by inducing sudden reduction of the DME and exacerbation of tangential traction of the posterior vitreous on the overlying macular retina. Lamellar macular hole seems to be a potential complication of pegaptanib injection even in patients without pretreatment clinically detectable vitreomacular traction.

Keywords

Diabetic macular edemaLamellar macular holeMacugenOptical coherence tomographyPegaptanib sodium

Copyright information

© Springer Science+Business Media B.V. 2011